A Study of TG103 Injection in Type 2 Diabetes Subjects

NCT05348122 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the effects of TG103 Injection in adults with Type 2 Diabetes to see how it impacts blood sugar levels over 17 weeks.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 240 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2022-06 · est. completion 2023-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05348122 ↗

Description as written by the study sponsor.

The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.

Treatments tested

TG103,Q2W also known as TG103 injection, subcutaneous injection,Q2W Drug

TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
TG103,QW also known as TG103 injection, subcutaneous injection,QW Drug

TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Placebo,Q2W also known as Placebo, subcutaneous injection,Q2W Drug

Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Placebo,QW also known as Placebo, subcutaneous injection,QW Drug

Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Dulaglutide,QW also known as Dulaglutide,subcutaneous injection,QW Drug

Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

Main thing measured	Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05348122 ↗